Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Adolescent Substance Use
Interventions: Guiding Good Choices; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 11 Years to 12 Years
Enrollment: 3,636 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Oakland, California • Aurora, Colorado • Detroit, Michigan

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, PF-04937319; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Phoenix, Arizona • Cypress, California • Miami, Florida

Conditions: Complications Wounds, Negative Pressure Wound Therapy, Wound Healing Delayed, Incisional, Panniculectomy, Incisional Negative Pressure Wound Therapy, Incisional Vac, Wound Vac, Obese, Renal Failure, Kidney Transplant; Complications, Wound Healing Complication
Interventions: Incisional Negative Pressure Wound Therapy, Standard Closure with Skin Glue, PICO (Smith&Nephew), Dermabond; Procedure · Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: irinotecan hydrochloride, alisertib; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Gastro Esophageal Reflux
Interventions: dexlansoprazole; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Posttraumatic Stress Disorders, Combat Disorders
Interventions: Web-PE Therapy, Therapist-Delivered Present-Centered Therapy; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Atlanta, Georgia • Philadelphia, Pennsylvania • Killeen, Texas + 1 more

Conditions: Autism Spectrum Disorder, Insomnia
Interventions: SweetDreams; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Months to 60 Months
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Eating Disorder Symptom
Interventions: Eat Breathe Thrive; Behavioral
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 266 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
Interventions: Radiation Therapy, Pertuzumab, Trastuzumab; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Tampa, Florida • Evanston, Illinois

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT003 MDI, PT005 MDI, Placebo MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®), Formoterol Fumarate 12 μg (Foradil® Aerolizer®), PT001 MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Clearwater, Florida • Charlotte, North Carolina • Medford, Oregon + 1 more

Conditions: Duchenne Muscular Dystrophy
Interventions: WVE-210201 (suvodirsen), Placebo; Drug
Lead sponsor: Wave Life Sciences USA, Inc.; Industry
Eligibility: 5 Years to 12 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: New Haven, Connecticut • Atlanta, Georgia • Kansas City, Kansas + 3 more

Conditions: Crohn's Disease
Interventions: Certolizumab pegol, Azathioprine; Biological · Drug
Lead sponsor: Gastroenterology Research of America; Other
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Maternal Obesity Syndrome
Interventions: cross-sectional; Other
Lead sponsor: University of Wyoming; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Laramie, Wyoming

Conditions: Cholesterol, Elevated, Elevated Cholesterol
Interventions: No Intervention; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Acid Reflux Disease, Heartburn
Interventions: Cell~vizio (Laser connfocal microscopy); Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Multiple Sclerosis
Interventions: Tolebrutinib, gemfibrozil, rifampicin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Advanced Squamous Tumors
Interventions: ABBV-711, Budigalimab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 6
States / cities: Duarte, California • Irvine, California • Chicago, Illinois + 3 more

Conditions: Erectile Dysfunction
Interventions: Nitric Oxide, Tadalafil, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: RHA Investments Ltd; Industry
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Pre Diabetes, Insulin Resistance, Diabetes Mellitus, Type 2
Interventions: Dietary, Oral Food Challege; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Mucosal Lentiginous Melanoma, Acral Melanoma, Melanoma
Interventions: Nilotinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 8
States / cities: Santa Monica, California • Aurora, Colorado • Tampa, Florida + 3 more

Conditions: Agitation
Interventions: risperidone; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 4 Years to 12 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Toothache
Interventions: Placebo gel, benzocaine; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 8
States / cities: Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 5 more

Conditions: Keratoconus
Interventions: Riboflavin Ophthalmic Solutions, UV-A Irradiation System; Drug · Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 13 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Westerville, Ohio

Conditions: Cystic Fibrosis
Interventions: RELiZORB (immobilized lipase) cartridge, Impact Peptide 1.5; Device · Other
Lead sponsor: Alcresta Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Hollywood, Florida • Boise, Idaho • Indianapolis, Indiana + 7 more

Search by objective public record fields.

Guiding Good Choices for Health

A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus

Incisional Negative Pressure Wound Therapy in High Risk Patients Undergoing Panniculectomy: A Prospective Randomized Controlled Trial

Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

Effectiveness of Physiologic Testing in PPI Non-Responders

A Comparison of Web-Prolonged Exposure (Web-PE) and Present-Centered Therapy (PCT) for PTSD Among Active-Duty Military Personnel

SweetDreams Sleep Study for Children With Autism

Efficacy of Eat Breathe Thrive, a Yoga-Based Program

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy

Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease

Hormonal Regulation of Postpartum Weight and Presence of Gut Peptides in Human Milk

A Pilot Study to Explore the Role of Gut Flora in Elevated Cholesterol

Confocal Laser Microscopy in Non Erosive Reflux Disease

Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

The Effects of a Nitrate Supplementation on Erectile Function

Precision Diets for Diabetes Prevention

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children

Benzocaine Gel Toothache Dose-Response Study

Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus

Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study